The wait is finally over! We're proud to introduce the AVA™ Emulation System, a first-of-its-kind high-throughput Organ-Chip platform. AVA is the first self-contained Organ-on-a-Chip workstation to fuse high-throughput microfluidic tissue culture, full environmental control, and real-time imaging into a single, compact benchtop unit. With capacity for 96 Organ-Chip “Emulations” per run, AVA transforms what’s possible in discovery, efficacy, and safety studies—delivering the biological depth of live human tissue at a scale once reserved for simple plate assays. AVA also delivers incredible time and labor savings. Hands-on, in-lab time is reduced by more than half, thanks to automated microscopy, remote monitoring, and the revolutionary new Chip-Array™ consumable that integrates 12 independent Organ-Chips into an SBS format for streamlined workflows with multichannel pipettes and automated liquid handlers. Why this matters: 📈 Human-relevant data at scale: AVA enables users to test dozens of compounds, doses, or time points in one experiment. A typical 7-day experiment can generate >30,000 time-stamped data points from daily imaging and effluent assays, with post-takedown omics pushing the total into the millions—providing a rich, multi-modal foundation to feed machine-learning pipelines for target discovery, lead optimization, and safety prediction. 🔬 See biology unfold in real time: AVA’s integrated microscope captures phase-contrast and three-channel fluorescence images while tissues remain under flow, enabling users to monitor tissue morphology and biomarker expression levels throughout the course of their experiment. ✅ Ready for tomorrow’s standards: As regulators such as the FDA and NIH start to pivot beyond animal testing, AVA delivers the human-specific data needed to empower confident decision-making and fast-track IND submissions. It's truly a new era of human-centric research, and we couldn't be more excited to be on this journey with you all! Meet AVA: https://xmrrwallet.com/cmx.pemulatebio.com/ava
Emulate, Inc.
Biotechnology Research
Boston, MA 26,594 followers
Our Organ-on-a-Chip technology provides a high-fidelity window into the inner workings of human biology and disease.
About us
Emulate, Inc. is the pioneer of Organ-on-a-Chip technology, enabling researchers to accurately replicate human tissue function and disease biology through next generation in vitro models. From target discovery to IND submission, Emulate aims to ignite a new era in human health research—one that reduces animal testing, cuts drug development costs, and accelerates the delivery of life-saving treatments. Emulate’s Organ-Chip platforms, consumables, and organ models help the world’s leading pharmaceutical, biotech, and academic teams generate human-relevant data that advance safer, more effective therapies.
- Website
-
http://xmrrwallet.com/cmx.pwww.emulatebio.com
External link for Emulate, Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Boston, MA
- Type
- Privately Held
- Founded
- 2014
- Specialties
- Understanding Disease, Personalized Health, Microfluidics, Human Biology, 3D in vitro models, and Organ-on-a-Chip Technology
Locations
-
Primary
Get directions
The Innovation & Design Building
Drydock Avenue
Boston, MA 02210, US
-
Get directions
-
Get directions
27 Drydock Ave
Boston, MA 02210, US
Employees at Emulate, Inc.
-
Jim Laur
Chief IP Officer, Cedars-Sinai & Managing Director, Cedars-Sinai Health Ventures
-
Elias S. Manolakos
Research Leader, Biomedical Data Science, AI/ML, Statistical Signal / Image / Data / Analysis
-
Nisa Leung
Health Care Investor / Entrepreneur, Forbes Midas Lister
-
Joel Z.
Front-end developer with over a decade of experience, developing rich user interfaces across various platforms and devices.
Updates
-
Looking for an easy way to catch up on the latest publications featuring Emulate technology? Check out the Summer 2025 issue of our Emulate Community Publications Digest! We're spotlighting all the recent research from our user community, spanning everything from patient-matched cancer models to spinal cord chips for modeling sporadic ALS. This digest is also a handy tool for easily compiling a complete list of publications tailored to your organ model and application of interest. Simply set your filter criteria, and the digest will generate a curated list of reference publications for you! Some examples of the types of lists you can generate include: 🔬 Cancer models of the digestive system 🦠 Infectious disease applications in the lung ☣️ Toxicology studies of the liver 🧫 Microbiome research of the reproductive system The possibilities are virtually endless. Download the digest today to start exploring! https://xmrrwallet.com/cmx.plnkd.in/dRaCqCM3
-
-
You might already be familiar with acronyms like OOC and MPS, but recently there's a new acronym that's been making headlines. 👀 If you've heard about "NAMs" but aren't sure what the term means, we've got just the blog for you! Check out our latest post to get up to speed on what NAMs are and how they're driving a new era of human-relevant decision-making in drug discovery and development! https://xmrrwallet.com/cmx.plnkd.in/eR5j2uiR #organchips #newapproachmethodologies #drugdiscovery #NAMs #FDA #NIH #invitro #insilico #inchemico
-
There's been a lot of discussion lately around the FDA's aspirational goal of phasing out animal testing by 2030. Our scientific founder, Donald Ingber, M.D., Ph.D., has written an insightful op-ed in The Scientist on whether or not we can realistically get there, and what this goal means for the future of drug development. Check it out below!
Founding Director, Wyss Institute for Biologically Inspired Engineering at Harvard University
The FDA aims to make animal testing the exception rather than the norm within 3-5 years, but is this possible? Advanced human cell-based assays, like organoids and Organ Chips, and computer models have advanced significantly since the FDA mandated animal testing in the 1930s, and especially in recent years. In some cases, these alternatives are better at predicting the human response to different drugs. Drug tests in animals fail to predict future reactions in humans more than 90% of the time. A recent study treated human Liver Chips with 27 different drugs, and they were found to be many times more accurate at predicting drug-induced liver injury in humans than past animal experiments. So, does that mean we’re ready to eliminate animal testing for good? Not quite yet. AI models are only as good as the data they ingest, so drugs developed with these models need further validation. Each new type of human culture model needs to be qualified in terms of its ability to predict human responses within a specific context of use. However, with the FDA’s new policies, such as providing incentives to pharmaceutical companies for including data from these human-relevant experimental models, we could be on our way to saving the lives of animals and enabling the development of safer and more effective drugs more quickly and at a lower cost. Read more in my op-ed from The Scientist. https://xmrrwallet.com/cmx.plnkd.in/eKTdsVrr
-
What's even better than getting an acceptance letter from the college of your dreams? Getting an acceptance letter from the FDA for your Qualification Plan in the ISTAND Program! We've been working with the FDA for the last year and a half to get our human Liver-Chip S1 qualified as an accepted drug development tool (DDT) for assessing the risk of drug-induced liver injury in investigational new drug (IND) submissions. Today we're proud to say that we've unlocked a new milestone towards achieving that goal! The FDA has approved our qualification plan, meaning that we can now start executing the series of experiments that ultimately will be used to qualify our Liver-Chip S1 as an FDA-approved tool for the prediction of drug-induced liver injury. This is an important step towards driving meaningful implementation of human-relevant science and brings us that much closer to achieving our mission of helping develop drugs, therapies, and cures for those who need them most. Thank you to everyone who has been with us during this journey. We're looking forward to continuing to drive a new human-centric era of drug development! PS - Miss the original announcement? Catch up on what the ISTAND program is and what our acceptance into the program means for the future of drug safety assessment here: https://xmrrwallet.com/cmx.plnkd.in/d_KXHnR3 #FDA #drugdevelopment #DILI #ISTAND #HumanRelevance #NAMs #OrganChip #LiverChip
-
-
With regulatory agencies such as the FDA and NIH continuing to announce exciting new policies and guidelines around the adoption of New Approach Methodologies (NAMs), you might be wondering where everything currently stands! We've summarized 5 key takeaways from our recent fireside chat with Tracy Beth Høeg, MD, PhD, who provided important insight on how NAMs are redefining how the FDA is interacting with pharmaceutical industry sponsors. Learn more about each of these takeaways here: https://xmrrwallet.com/cmx.plnkd.in/dJiH-EUz #FDA #NIH #NAMs #newapproachmetholodies #invitro #organchips #sciencepolicy #pharma #drugdiscovery #lifescience #research
-
-
We're #hiring a new Infrastructure Engineer III in Boston, Massachusetts. Apply today or share this post with your network.
-
In our latest blog, we're recapping all the excitement from #MPS2025! Check it out to catch up on the latest technology and innovative research that was unveiled at the conference! https://xmrrwallet.com/cmx.plnkd.in/ebMRCRrX
-
We're #hiring a new Director of Software Engineering in Boston, Massachusetts. Apply today or share this post with your network.